Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Hosted on MSN3d
FDA expands Novartis’ Kisqali label to include early breast cancer patients
"FDA expands Novartis’ Kisqali label to include early breast cancer patients" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
pharmaphorum25d
Novartis builds case for Leqvio with monotherapy data
Novartis said at launch Leqvio was likely to be a slow-growing brand, but it is now showing clear signs of gathered momentum, with sales in the first half of this year rocketing 137% to $333 million.
Investopedia6d
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...
FiercePharma4d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
Benzinga.com17d
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Novartis is trading at 14.2 times its projected 2025 EPS, representing an approximately 8% premium over the European Biopharma sector. Stock buyback scheme could potentially boost the stock, but ...
Bloomberg L.P.6d
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...
Reuters29d
Novartis receives binding offer from Siemens Healthineers for molecular imaging business
Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
Yahoo Finance1mon
Novartis and Versant launch Borealis Biosciences with $150m
Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...
The Financial Times29d
Siemens Healthineers boosts cancer imaging with €200mn Novartis deal
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Siemens Healthineers has agreed to buy part of a Novartis business that specialises in producing ...